A retrospective real-world analysis of 89 patients found high response rates and manageable safety for isatuximab, carfilzomib, and dexamethasone (Isa-Kd) in relapsed or refractory multiple myeloma. The regimen produced an overall response rate of 83.8% in routine practice, with deep responses in a substantial share of patients. The study emphasizes patient populations often underrepresented in trials—including those with renal impairment and extramedullary disease. Median progression-free survival and overall survival were not reached during the study observation window, with restricted mean PFS reported as 23.8 months. These findings help ground expectations for Isa-Kd outside controlled settings and inform real-world treatment sequencing decisions for hematology clinicians.
Get the Daily Brief